In several brain diseases, including multiple sclerosis and spinal muscular atrophy, effective disease-modifying treatments can normalize NfL levels, and reduction in NfL levels is associated with the clinical effectiveness of the treatment.150,151. This evidence concerns the gene NEFL and proximal spinal muscular atrophy.